Skip to content

Preferred Stock at other companies

Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$0
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$0
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$0
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$0

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Sarepta Therapeutics, Inc.'s preferred stock?
Sarepta Therapeutics, Inc. (SRPT) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.